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INTRODUCTION: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a treatment option
in the second- or third-line palliative setting in EGFR wild-type (wt) non–small cell lung cancer (NSCLC) patients.
However, response rates are low, and only approximately 25% will achieve disease control. Early prediction of
treatment resistance could accelerate discontinuation of ineffective treatment and reduce unnecessary toxicity. In
this study, we evaluated early changes on 18F-fluoro-D-glucose (F-18-FDG) positron emission tomography/
computed tomography (PET/CT) and in total plasma cell-free DNA (cfDNA) as markers of erlotinib response in
EGFR-wt patients.METHODS: F-18-FDG-PET/CT scans and blood samples were obtained prior to erlotinib initiation
and were repeated after 1 week (PET/CT) and 1 to 4 weeks (blood sample) of treatment. Level of cfDNA was
measured by droplet digital polymerase chain reaction. Percentage change (% ) in SULpeak and total lesion
glycolysis (TLG) on FDG-PET/CT and in plasma cfDNA was correlated to radiological response, progression-free
survival (PFS), and overall survival (OS). RESULTS: Fifty patients were prospectively enrolled. A significant
correlation was found between CT response and % TLG (P = .003). All patients with early metabolic progression
showed radiological progression. Increased % TLG and % cfDNA were significantly correlated with shorter PFS
(P = .002 and P = .004, respectively) and OS (P = .009 and P = .009, respectively). Multivariate analysis
indicated % cfDNA to be the strongest predictor of OS. CONCLUSION: Early increase in TLG on F-18-FDG-PET/CT
correlates with radiological progression, and shorter PFS and OS. Early increase in cfDNA predicts shorter PFS and
OS. Both assessments are promising tools for early detection of nonresponders and reduced OS in TKI-treated
EGFR-wt NSCLC patients.
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Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth
factor receptor (EGFR) have emerged as important treatment options
in non–small cell lung cancer (NSCLC) patients. Activating
mutations in the EGFR gene have proven to be crucial predictors
of treatment response [1]. However, mutation status cannot solely
predict outcome because a fraction of EGFR wild-type (wt) patients
also benefits from the treatment. Hence, EGFR-TKIs are a treatment
option in the second- or third-line palliative setting in these patients
[2,3]. However, additional clinical tools are needed to distinguish
nonresponders from responders and thereby increase the ability to
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effective treatment can be offered to the patient.
An early response assessment on a 2′-deoxy-2′-[18F]
fluoro-D-glucose (F-18-FDG) positron emission tomography/com-
puted tomography (PET/CT) scan performed during the first 2 weeks
of treatment is a promising new tool for treatment response
prediction. A change in FDG uptake has been visualized as early as
after 2 days of TKI treatment [4,5], and studies have shown an
association between the early metabolic response and treatment
outcome [4–8]. However, these studies have evaluated patients with
either unselected or mixed EGFR mutation status. Patients with
EGFR activating mutations have a considerably better effect on
EGFR-TKIs, and whether early FDG-PET response assessment is
predictive in a cohort consisting exclusively of EGFR-wt patients is
still unknown. Furthermore, in prior studies, standardized uptake
value (SUV) metrics have been used for FDG-PET response
assessment; yet, these parameters only represent a change in FDG
uptake in a single voxel of the tumor or a small region of interest in
the tumor. A more informative parameter could be the volume-based
parameter total lesion glycolysis (TLG) because it reflects the entire
metabolic tumor burden by combining volumetric data of tumors
with the metabolic activity. In chemotherapy-treated NSCLC
patients, two studies have reported TLG to be superior to SUVmax
and SUVpeak for early response prediction [9,10], and this could also
apply for TKI-treated patients.
Total plasma cell-free deoxyribonucleic acid (cfDNA) is appearing
as a new potential biomarker in cancer. cfDNA is believed to be shed
by both normal cells and tumor cells. The amount found in the
circulation increases when cells are undergoing apoptosis or necrosis.
Higher levels have been identified in cancer patients compared with
noncancer patients [11–13], and the level has been suggested to
reflect the tumor burden in patients. Therefore, changes in cfDNA
concentration could be associated with treatment response; however,
the predictive value of an early change in cfDNA value during TKI
treatment has not yet been investigated.
Thus, changes in 18-F-FDG-PET signals as well as changes in
cfDNA levels are two promising methods for early response
assessment. Hence, the aim of this study was to evaluate the
predictive value of each of these methods in a cohort of
advanced-stage EGFR-wt NSCLC patients treated with erlotinib in
second or third line. Moreover, we compared the value of the two
FDG-PET–derived parameters, TLG and SULpeak, for the early
metabolic response prediction.
Material and Methods
Patients and Study Design
In this prospective, single-center study, 67 patients with stage III or IV
NSCLC were enrolled from April 2013 until August 2015 at the
Department of Oncology, Aarhus University Hospital, Denmark.
Patients were candidates for enrolment if they were eligible to initiate
treatment with erlotinib in a palliative setting.Details on inclusion criteria
and study treatment have been described previously [14]. The study was
approved by the Central Denmark Region Committees on Biomedical
Research Ethics (no. 1-10-72-19-12) and reported to ClinicalTrial.gov
(NCT02043002). Each patient gave written informed consent before
inclusion. For the purpose of this work, we included patients from the
enrolled cohort whowereEGFR-wt, were treated in second- or third-line,
and had undergone paired scans and/or paired blood samples.18-FDG-PET/CT scans were performed pretreatment and after 7
to 10 days of erlotinib treatment. Blood samples were collected prior
to erlotinib initiation and after 1 to 4 weeks of treatment. CT scans of
the chest and abdomen were conducted before and after 9 to 11 weeks
of treatment or earlier on clinical indication. Further evaluation CT
scans were performed every 12 weeks during the treatment period.
Neuroimaging was performed on clinical indication. Routine clinical
and biochemical evaluation was performed every fourth week in the
first 12 weeks and subsequently every sixth week.
Data on clinical characteristics and response were collected
from medical files. Testing for EGFR mutations and anaplastic
lymphoma kinase (ALK) translocations had been performed as part
of the diagnostic workup and is described in detail in Supplementary
File 1.
Response Assessment on FDG-PET/CT and CT Imaging
All F-18-FDG-PET/CT scans were performed on a combined
PET/CT scanner (Siemens Biograph TruePoint 40) at the
Department of Nuclear Medicine and PET-Centre, Aarhus Univer-
sity Hospital, Denmark. The imaging protocol is described in
Supplementary File 1. Same scanner model, protocol for acquisition,
and reconstruction software were used in all patients. Data on amount
of injected 18-F-FDG, uptake time, and plasma glucose concentra-
tion are shown in Supplementary Table 1.
An experienced nuclear medicine physician blinded to the patient
outcome analyzed all PET/CT scans using Siemens Syngo.via
software. All SUV values were normalized to lean body mass
(SUL). SULpeak and whole-body TLG were calculated according to
the Positron Emission Tomography Response Criteria in Solid
Tumors (PERCIST) 1.0 guideline [15] (described in Supplementary
File 1). TLG could not be evaluated in two patients: in one patient
due to carcinomatosis of the lung and in one patient due to multiple
small lesions on the follow-up scan making tumor-volume assessment
impossible. Percentage change (%Δ) in SULpeak and whole-body
TLG between pretreatment and follow-up scan was calculated as:
(follow-up value − pretreatment value)/pretreatment value × 100.
Metabolic response based on %ΔSULpeak was classified according to
the PERCIST 1.0 guideline, whereas %ΔTLG was classified using a
cutoff value of 25% based on observations by Kahraman et al. [16]
(see Supplementary File 1).
Radiological response was evaluated on the first CT scan performed
after initiation of erlotinib and quantified as %Δ in sum of longest
diameter (SLD) of target lesions according to Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1 criteria [17].
Quantification of Total Plasma cfDNA
A peripheral blood sample of 10 ml was collected at each time
point. The samples were centrifuged (1400g for 15 minutes), and
plasma was isolated. Plasma was subsequently frozen at −80°C until
further analysis. Total cfDNA was purified from 2 ml of plasma by
use of the QIAamp circulating Nucleic Acid kit (Qiagen, Hilden,
Germany) according to the manufacturer's protocol and eluted in a
volume of 100 μl of TE buffer. To quantify the amount of cfDNA,
the beta-2-microglobulin (B2M) gene was measured as previously
described [18]. To account for a possible overestimation of the total
cfDNA by accidental leukocyte contamination in the preanalytical
phase, a unique B-cell immunoglobulin DNA rearrangement (PBC) was
quantified [18]. The two genes were quantified in duplicates by
droplet digital polymerase chain reaction (ddPCR, Bio-Rad QX200)
Translational Oncology Vol. 9, No. 6, 2016 Erlotinib Response in EGFR Wild-Type NSCLC Winther-Larsen et al. 507in a multiplex reaction using 5 μl of sample. Primers (Eurofins
Genomics), probes (Integrated DNA technology), and ddPCR
conditions are described in Supplementary File 1. Samples with a
PBC/B2M ratio larger than 0.1% were excluded from further analysis
as previously described [18]. As the level of cfDNA varies between
patients, %Δ in cfDNA level from pretreatment to follow-up was
calculated.
Statistical Analysis
Correlations between metabolic response, change in total plasma
cfDNA, and radiological response were calculated using Fisher’s exact
test (categorical variables), Spearman's rank correlation coefficient
(continuous variables), and Mann-Whitney U test (median values).
In calculation of correlation between metabolic and radiological
response, patients classified with stable disease (SD) or partial
response (both metabolic and radiologic) were combined because of
the low number of patients classified with partial response. Predictive
accuracy of PET and cfDNA with respect to nonprogression on the
CT scan was evaluated by using receiver operating characteristics
(ROC) analysis (area under the curve [AUC]). Overall survival (OS)
was measured from start of erlotinib treatment until death of any
cause or last follow-up date (November 30, 2015). Progression-free
survival (PFS) was defined as the time from initiation of erlotinib to
first documentation of either clinical or radiological progression or
death. If erlotinib treatment was ended without occurrence of
progression or death, patients were censored at the time of
discontinuation. Patients still undergoing treatment with erlotinib
on the last follow-up date were censored at that day. Estimates of
median PFS and OS were calculated by the Kaplan-Meier method
and compared by the log-rank test. The Cox proportional-hazards
model was used to calculate crude and adjusted hazard ratios (HRs).
Clinical variables were dichotomized except for age (continuous).
FDG-PET parameters and level of cfDNA were tested as continuous
variables to avoid bias created by the cutoff values selected for
classification of the variables. All tests were two-sided, and P values
less than .05 were considered to be statistically significant. Statistical
analyses were performed using SPSS statistics version 20.0 for
Windows (IBM SPSS Statistics, Chicago, IL). STATA version 13
(Stata Corporation, College Station, TX) was used for preparation of
Kaplan-Meier curves.Results
Patients
A total of 50 patients were included in the final analysis. A flow
diagram of inclusion is shown in Figure 1. Patient characteristics are
shown in Table 1. Follow-up data were available for all patients. At
the last follow-up date, one patient was still undergoing erlotinib
treatment and nine patients were still alive. Erlotinib was
discontinued in patients because of either radiological or clinical
progression of disease (n = 41), toxicity (n = 7), or death (n = 1).
Correlation between FDG-PET/CT and CT Response
A significant correlation was found between radiological response
andmetabolic response on FDG-PETwhenTLGwas used for response
assessment (P = .003) (Table 2). Twelve patients were classified with
metabolic progression, and all showed radiological progression.
Thereby, 44% (12/27) of patients showing progression on CT could
be identified by early FDG-PET. The %ΔTLGs found in the 12patients classified with metabolic progression are shown in
Supplementary Table 2. Likewise, assessment of the %ΔSULpeak
showed a high predictive value of early metabolic progression
(Table 2). However, only 21% (6/28) of patients demonstrating
radiological progression could be identified by this measure. When
continuous %Δ in early PET response was correlated to %ΔSLD
measured on the CT scan, a correlation was found using both PET
parameters (%ΔTLG: Spearman's correlation coefficient = 0.356,
P = .024; %ΔSULpeak: Spearman's correlation coefficient =
0.327, P = .034). The ROC analyses showed that the prediction
of nonprogression by %ΔTLG was 0.93 (95% CI, 0.84-1.00;
P b .001) and by %ΔSULpeak was 0.85 (95% CI, 0.74-0.96;
P b .001) (Supplementary Figure 1).
Correlation Between Total Plasma cfDNA Level and
CT Response
Leukocyte DNA contamination was found in samples from nine
patients, and these patients were excluded from further analysis. The
overall median %ΔcfDNA was 49% (range, −91 to 6249). A median
increase of 58% was seen in patients classified with radiological
progression, whereas only a median increase of 5% was found in
patients classified with SD (Table 2); however, the difference was not
statistically significant. Of the 18 patients showing radiological
progression, 13 patients (72%) showed an increase in cfDNA,
whereas the same fraction was 50% in patients with SD. No
significant correlation was found when the continuous %ΔSLD was
correlated to continuous %ΔcfDNA (Spearman's correlation coeffi-
cient = 0.206, P = .284). In line with this, the ROC analysis showed
a relative poor AUC of 0.62 (95% CI, 0.45-0.86; P = .162)
(Supplementary Figure 1).
Correlation Between FDG-PET/CT Scans, cfDNA Level, and
Survival
The overall median PFS of all patients was 2.7 months (95%
CI, 2.5-2.9), and the median OS was 6.0 months (95% CI, 3.7-8.3).
Kaplan-Meier curves of PFS and OS according to FDG-PET response
are shown in Supplementary Figure 2. Patients classified with
progression by any of the two assessments had a significantly shorter
PFS than patients classified with nonprogression (P = .014 [SULpeak]
and P = .024 [TLG]). Univariate Cox regression analyses showed
that an increase in %ΔTLG and %ΔcfDNA was significantly
correlated to shorter PFS (Table 3) and shorter OS (Table 4). A trend
toward an association with PFS was found for %ΔSULpeak, whereas
there was no correlation to OS. To evaluate the independent impact
of %ΔTLG and %ΔcfDNA, multivariate Cox regression analyses
were performed. Increase in %ΔTLG and %ΔcfDNA both remained
independent predictors of shorter PFS (%ΔTLG: adjusted HR =
1.02 [95% CI, 1.00-1.03], P = .045; % ΔcfDNA: adjusted HR =
1.001 [95% CI, 1.00-1.002], P = .017) (Table 3). Furthermore,
increase in %ΔcfDNA remained an independent predictor of shorter
OS (Table 4), whereas %ΔTLG did not show an independent
correlation.
Discussion
In this prospective study, we evaluated two different methods for early
response assessment in EGFR-wt NSCLC patients treated with
erlotinib because such a method is highly needed in this subgroup of
patients. We demonstrated that an early change in TLG, measured on
an FDG-PET/CT scan performed after 1 week of erlotinib treatment,
Screened for enrollment (N=106)
Included
(N=50)
• No pre-treatment blood 
sample (N=2)
• No follow-up blood 
sample (N=4)
• Withdrew content (N=4)
• EGFR mutation positive 
tumor (N=10)
• Received erlotinib as 1st 
line of treatment (N=2)
• Neither paired FDG-PET 
scans or paired blood 
samples (N=1)
Enrolled 
(N=67)  
• Declined to participate 
(N=38)
• Failed inclusion criteria 
(N=1)
Analyzed
Paired blood samples (N=44)
• No follow-up FDG-PET 
scan (N=1)
Analyzed
Paired FDG-PET scans (N=49)
cfDNA data available 
(N=35)
• Leukocyte contamination 
(N=9)
TLG assessment 
(N=47)
SULpeak
assessment 
(N=49)
• TLG 
assessment 
impossible 
(N=2)
Figure 1. Consort diagram of patient inclusion.
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treatment when a cutoff value of 25% was used. Most importantly,
we found a high negative predictive value of early metabolic
progression. All patients with progression after 1 week of treatment
showed radiological progression. Thereby, 44% of all patients
showing CT progression could be identified after only 1
week. Moreover, five out of six patients classified with partial
metabolic response on the PET scan showed nonprogression on
the CT scan. Lastly, the early metabolic change correlated with
both PFS and OS.
Our results are consistent with findings in previous studies
assessing the predictive value of an early metabolic response in
TKI-treated NSCLC patients [5–8,19–21]. Despite variations in the
timing of the early FDG-PET scan (2-14 days), all studies
demonstrated an association between early PET response and
outcome. However, these studies were performed in patients with
either unselected or mixed EGFR mutation status. Our study is the
first to show that early metabolic response monitoring is a usefulpredictor of outcome in a cohort consisting of only EGFR-wt
patients. This is clinically important because biomarkers for
EGFR-TKI treatment are highly needed in this patient subgroup
where disease stabilization is only seen in around 25% and tumor
response in approximately 8% [22]. Our findings bear important
clinical significance because identification of resistant patients after
just 1 week of treatment can lead to early discontinuation of
ineffective treatment. This will markedly reduce the risk of
unnecessary toxicity and increase the chance of receiving other
potentially effective treatments before worsening of performance
status.
We compared the effectiveness of two different parameters for PET
response assessment. Both parameters were found to correlate with
the change in SLD on the CT scan and show a high accuracy for
prediction of nonprogression. However, TLG assessment was the
only one of the two parameters significantly correlated to PFS and
OS. Overall, our data indicate a superiority of early TLG assessment
compared with SULpeak for early response monitoring in TKI-treated
Table 1. Clinical Characteristics (N = 50)
Characteristics n (%)
Age
Median years (range) 68 (49-83)
Sex
Female 22 (44)
Male 28 (56)
PS, ECOG
0 4 (8)
1 36 (72)
2 10 (20)
Smoking status
Never 1 (2)
Former * 38 (73)
Current 12 (23)
Unknown 1 (1)
Stage
IIIa 2 (4)
IIIb 2 (4)
IV 46 (92)
Brain metastases
Yes 7 (14)
No 45 (86)
Histology
Adenocarcinoma 42 (84)
Squamous cell 8 (16)
EML4-ALK gene fusion †
Positive 0
Negative 27 (54)
Unknown 23 (44)
Erlotinib treatment
2nd line 41 (79)
3rd line 9 (17)
Prior treatment
1st line
Carboplatin/vinorelbine ‡ 27 (54)
Carboplatin/vinorelbine /bevacizumab § 23 (46)
2nd line ¶
Pemetrexed 5 (56)
Docetaxel 4 (44)
Timing of PET scans
Days from pretreatment PET to erlotinib start, median (range) 1 (0-21)
Days from erlotinib start to follow-up PET, median (range) # 8 (2-23)
Timing of CT scans
Days from pretreatment CT to erlotinib start, median (range) 14 (4-120)
Days from erlotinib start to evaluation CT, median (range) 72 (20-92)
Timing of blood samples
Days from pretreatment sample to erlotinib start, median (range) 3 (0-24)
Days from erlotinib start to follow-up sample, median (range) †† 26 (6-58)
PS, performance status; ECOG, Eastern Cooperative Oncology Group; EML4-ALK, echinoderm
microtubule-associated protein-like 4-anaplastic lymphoma kinase.
* Former smoker was defined as having stopped smoking at time of diagnosis.
† Only patients with adenocarcinoma were tested.
‡ Carboplatin day 1 (AUC 5) and vinorelbine day 1 and day 8 (60-80 mg/m2 [PO]) every 3 weeks for a
maximum of four cycles.
§ Bevacizumab (7.5 mg/m2 IV day 1) was given in combination with chemotherapy. Patients with disease
control received subsequent maintenance therapy every 3 weeks until progression or toxicity.
¶ Only including patients treated with erlotinib in third line.
# Four patients were not scanned between 7 and 10 days after initiation of erlotinib but instead after 2, 5,
14, and 23 days, respectively.
Four patients were scanned later than 9 to 11 weeks of treatment (3 patients 12 weeks after and 1 patient
13 weeks after). Thirteen patients had their CT scan performed earlier because of suspicion of progression.
†† One patient had the follow-up sample collected before 1 week of erlotinib treatment (after 6 days) and 7
patients later than 4 weeks (30, 31, 32, 35, 40, 48, and 58 days, respectively).
Table 2. PET Response and Change in Level of Total Plasma cfDNA in Correlation to CT
Response
CT Response *
PR SD PD Total
PET response using %ΔSULpeak assessment † (P = .076 ‡)
PMR 0 3 2 5 (12%)
SMD 1 11 20 32 (74%)
PMD 0 0 6 6 (14%)
Total n (%) 1 (2%) 14 (33%) 28 (65%) 43 (100%)
PET response using %ΔTLG assessment § (P = .003 ‡)
PMR 1 4 1 6 (15%)
SMD 0 9 14 23 (56%)
PMD 0 0 12 12 (29%)
Total n (%) 1 (2%) 13 (32%) 27 (66%) 41 (100%)
Total plasma cfDNA (P = .172 ¶)
Median %ΔcfDNA (range) 5% (−91 to 401) 58% (−31 to 6249) 47% (−91 to 6249)
Total n (%) 12 (40%) 18 (60%) 30 (100%)
PR, partial response; PD, progressive disease; PMR, partial metabolic response; SMD, stable
metabolic disease; PMD, progressive metabolic disease.
* An evaluation CT scan was performed in 44 patients. CT response was defined according to RECIST
version 1.1 criteria.
† Response was defined according to PERCIST 1.0 guideline.
‡ In calculation of the P value, PMR and SMD as well as PR and SD were combined. P value was
calculated by the Fisher’s exact test.
§ PMR was defined as a reduction in TLG of minimum 25%, PMD as an increase in TLG of minimum
25%, and SMD as a change not classified as PMR or PMD.
¶ P value was calculated by the Mann-Whitney U test.
Table 3. Univariate and Multivariate Cox Regression Analysis of PFS (N = 50)
Variables HR (95% CI) P Value Adjusted HR (95% CI) P Value
Age * 1.01 (0.97-1.05) .596
Sex
Female 0.65 (0.35-1.22) .180
Male 1.00
Histology
Adenocarcinoma 0.95 (0.43-2.07) .892
Squamous cell 1.00
Smoking
Never or former † 0.99 (0.49-1.99) .978
Current 1.00
PS, ECOG
0-1 1.08 (0.45-2.57) .872
2 1.00
Stage
IV 0.40 (0.12-1.37) .144
III 1.00
Brain metastases
Yes 3.31 (1.34-8.21) .010 34.54 (2.75-433.56) .006
No 1.00 1.00
Erlotinib treatment
1st or 2nd line 0.85 (0.40-1.80) .668
3rd line 1.00
%ΔTLG * 1.02 (1.01-1.03) .002 1.02 (1.00-1.03) .045
%ΔSULpeak * 1.01 (1.00-1.02) .100
%ΔcfDNA * 1.001 (1.00-1.001) .004 1.001 (1.00-1.002) .017
* Evaluated as a continuous variable.
† Former smoker was defined as having stopped smoking at time of diagnosis.
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information of the complete metabolic tumor burden in the patient
and, in addition, includes the metabolic activity of the tumor, which
serves as a marker of tumor aggressiveness. One prior study has
evaluated TLG assessment for early response monitoring in
erlotinib-treated NSCLC patients. In 30 patients, a trend toward a
correlation between metabolic response and longer PFS was foundwhen a 20% or a 30% cutoff value was used for defining a response
[16]. No comparison to other SUV metrics was performed in their
study. However, a comparison between the value of SUVmax,
SUVpeak, MTV, and TLG assessments on FDG-PET for detecting
early response to chemotherapy was performed in 52 advanced-stage
NSCLC patients [9]. In consistency with our data, they found TLG
to be the sole parameter significantly correlated to PFS and OS.
In addition, we evaluated the predictive value of an early change in
total plasma cfDNA. We demonstrated that an increase in plasma
Table 4. Univariate and Multivariate Cox Regression Analysis of OS (N = 50)
Variables HR (95% CI) P Value Adjusted HR (95% CI) P Value
Age * 1.00 (0.97-1.04) .845
Sex
Female 0.63 (0.33-1.22) .169
Male 1.00
Histology
Adenocarcinoma 0.99 (0.43-2.26) .977
Squamous cell 1.00
Smoking
Never or former † 1.46 (0.69-3.07) .322
Current 1.00
PS, ECOG
0-1 0.59 (0.28-1.26) .177
2 1.00
Stage
IV 0.55 (0.19-1.58) .267
III 1.00
Brain metastases
Yes 3.47 (1.45-8.11) .004 17.00 (2.94-98.44) .002
No 1.00 1.00
Erlotinib treatment
1st or 2nd line 1.19 (0.52-2.72) .676
3rd line 1.00
%ΔTLG * 1.02 (1.00-1.03) .009 1.01 (1.00-1.02) .178
%ΔSULpeak * 1.00 (0.99-1.02) .716
%ΔcfDNA * 1.001 (1.00-1.001) .009 1.001 (1.00-1.001) .043
* Evaluated as a continuous variable.
† Former smoker was defined as having stopped smoking at time of diagnosis.
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associated with a shorter PFS and shorter OS. In the group of patients
showing radiological progression, we found a higher median
percentage increase in cfDNA and a higher fraction of patients with
an increase in cfDNA compared with patients classified with SD.
However, this difference did not reach statistical significance. We are
the first to evaluate an early change in plasma cfDNA in TKI-treated
NSCLC patients. The dynamics of plasma cfDNA have been
evaluated in NSCLC patients treated with chemotherapy; however,
studies have showed conflicting results [23–26]. Yet, none of the
previous studies have accounted for a potential leukocyte DNA
contamination and excluded blood samples with high contribution of
leukocyte DNA as done in our study. We found contamination to be
a problem in a substantial number of samples (11%), and a possible
overestimation of cfDNA concentrations in prior studies could have
influenced their results.
Previous studies have proposed total plasma cfDNA level to be a
marker of tumor burden. Baseline plasma cfDNA values were found
to correlate to both nodal stage and number of metastases in 134
NSCLC patients [27], and a significant decrease in the level of plasma
cfDNA was found after tumor resection in 20 low-stage patients [12].
Our findings support these data and suggest plasma cfDNA as a
promising predictor of PFS and OS in EGFR-wt NSCLC patients
treated with erlotinib.
The strengths of our study are the prospective nature and the
standardization of the FDG-PET imaging. All PET scans were
performed on the same scanner model and with use of the same
protocol for acquisition and reconstruction software, reducing the risk
of interindividual variability of the scans. Moreover, handling of
blood samples was performed in one laboratory by trained
technicians, and we excluded samples with leukocyte contamination.
Lastly, complete clinical data including the EGFR mutation status
were available in all patients. In contrast, our work had somelimitations to consider. Although it is one of the largest studies in the
field, the impact of the study could have been increased if a higher
number of patients had been included. Additionally, as the follow-up
blood samples were collected in a range from 6 to 58 days after
initiation of erlotinib, we are unable to define the optimal time point
for early assessment of cfDNA.
Conclusion
In conclusion, our study demonstrated TLG assessment on an early
FDG-PET/CT scan to be a promising predictor of response and
survival in advanced-stage EGFR-wt NSCLC patients treated with an
EGFR-TKI and to be a more robust method for response assessment
than SULpeak. Moreover, we showed that an early increase in the level
of total plasma cfDNA predicted shorter PFS and OS, but no
correlation with radiological response was seen. A combination of the
two assessments could be promising for response monitoring in this
patient population. Because of the low number of patients included in
our study, we could not evaluate the combination of the two
assessments, and future larger, prospective, randomized studies are
needed to accomplish this.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2016.09.003.
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